12/09/18 - 13/09/18: 7th Annual Pharma Anti-Counterfeiting & Serialisation 2018
When: 12th & 13th September 2018
Where: Sheraton Skyline Hotel, London Heathrow, UK
Categories: Lectures & Conferences
Event website: http://www.virtueinsight.com/pharma/7th-Annual-Pharma-Anti-Counterfeiting--Serialisation-2018/
About this Event:
The worldwide market for pharmaceuticals is projected to grow from around $1 trillion in 2015 to $1.3 trillion by 2020, representing an annual growth rate of 4.9 percent. Counterfeit drugs have become a $200-billion-a-year global industry, which despite on-going crackdowns by the authorities is a growing problem. With sales ranging from €150 billion to €200 billion (US$163 billion to $217 billion) per year, according to industry estimates, counterfeit pharmaceuticals are the most lucrative sector of the global trade in illegally copied goods. According to a report t is predicted that the global anti-counterfeit packaging market in food and pharmaceuticals is forecasted to atthe tain market value of $142.7 billion by 2020 from $57.4 billion in 2013, growing at 13.9% CAGR during 2013 to 2020’.
The anti-counterfeit packaging market size is estimated to grow from USD 82.05 Billion in 2015 to reach USD 153.95 Billion by 2020, at a CAGR of 13.41%. IP Theft. According to a report, £9.2bn has been lost through intellectual property (IP) theft, £7.6bn to industrial espionage and £2.2bn from extortion. Anti-Counterfeit Packaging Market Size will Worth to $184.87 Billion by 2025. Track and trace technology products are expected to grow at a CAGR of over 9% by revenue, from 2016 to 2025 driven by the superior product detection and tracking through the supply chain. Track and Trace Solutions Market worth 3.93 Billion USD by 2023
All set for early 2019, the Delegated Act on safety features for the European Union (EU) Falsified Medicines Directive (FMD) has pharmaceutical companies, parallel importers, wholesalers, and pharmacies facing a close-fitting timeline to address extensive serialisation, compliance reporting, and verification requirements. The Delegated Act includes several unexpected rules that add complexity to FMD planning and preparation. Many supply chain companies have raised questions related to the impending Delegated Act requirements and we could find answers for all of them at our conference.
This conference overviews and integrates the business and technical problems that pharmaceutical companies should be aware of in order to fight the major global problem of counterfeit medicines. In addition to discussion of the problems, this conference addresses serialisation, track and trace analytical techniques scientists use to detect counterfeits and identifying solutions to the threat of counterfeit medical products. It gives us immense pleasure in welcoming you to “7th Annual Pharma Anti-Counterfeiting & Serialisation 2018 – “Competences to Combat Counterfeits”